The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2023 | Treating CLL in the UK: current and future outlooks
Nicolas Martinez-Calle, MD, PhD, Nottingham University Hospitals NHS Trust, Nottingham, UK, comments on the current and future treatment of chronic lymphocytic leukemia (CLL) within the National Health Service (NHS) framework in the UK. Dr Martinez-Calle comments on the increasing number of options available to treat patients with CLL, explaining how it will be important to identify differences between these treatments in order to choose the best treatment option for each patient. Dr Martinez-Calle also discusses the economic and patient benefits of fixed-duration therapies. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
